FDA Approves Alzheimer’s Drug; Hopes Dashed For Medicare Price Negotiation Bill This Year

By John Wilkerson / June 7, 2021 at 4:50 PM
A little more than a week after the Senate parliamentarian doused what little hope there was for drug pricing legislation this year, FDA approved a treatment for Alzheimer’s that many warn could be costly to Medicare, though the cost to taxpayers of aducanumab will depend on whether Medicare restricts coverage. The Senate parliamentarian’s recent ruling stops Democrats from recycling a third time the 2021 budget resolution and reconciliation instructions that was used for the American Rescue Plan, several sources say...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.